"Early Circulating Tumor DNA Dynamics Predict Overall Survival in Solid Tumors"
Saw this study posted elsewhere and thought it might be of interest...
Key excerpts :
A total of 162 studies across advanced solid tumors met the inclusion criteria, and four meta-analyses were reviewed separately.
Although ctDNA clearance yielded the strongest associations, ≥50% decrease and any decrease in ctDNA from baseline were also consistently prognostic, whereas increases in ctDNA were associated with poorer OS. Additionally, all four meta-analyses reported significant associations between ctDNA decrease or clearance and improved OS.
Early reductions in ctDNA are associated with improved OS across diverse tumor types and therapeutic contexts, underscoring the robustness of ctDNA dynamics as a prognostic biomarker in clinical trials. Standardization of collection timing, MR thresholds, and assay approaches will be essential for advancing on-treatment ctDNA reductions toward regulatory qualification as an early end point.
Link:
https://ascopubs.org/doi/10.1200/OA-26-00005?
________________________________________________________________
As always, I remain... BULLISH
https://www.youtube.com/watch?v=Xm3HU5f3vzQ
Disclaimer: None of my posts should be considered investment advice as they are speculative in nature, based solely on publicly available information.
Saw this study posted elsewhere and thought it might be of interest...
Key excerpts :
A total of 162 studies across advanced solid tumors met the inclusion criteria, and four meta-analyses were reviewed separately.
Although ctDNA clearance yielded the strongest associations, ≥50% decrease and any decrease in ctDNA from baseline were also consistently prognostic, whereas increases in ctDNA were associated with poorer OS. Additionally, all four meta-analyses reported significant associations between ctDNA decrease or clearance and improved OS.
Early reductions in ctDNA are associated with improved OS across diverse tumor types and therapeutic contexts, underscoring the robustness of ctDNA dynamics as a prognostic biomarker in clinical trials. Standardization of collection timing, MR thresholds, and assay approaches will be essential for advancing on-treatment ctDNA reductions toward regulatory qualification as an early end point.
Link:
https://ascopubs.org/doi/10.1200/OA-26-00005?
________________________________________________________________
As always, I remain... BULLISH
https://www.youtube.com/watch?v=Xm3HU5f3vzQ
Disclaimer: None of my posts should be considered investment advice as they are speculative in nature, based solely on publicly available information.
3
